Chemomab Therapeutics Ltd. Statistics
Share Statistics
Chemomab Therapeutics Ltd. has 18.86M shares outstanding. The number of shares has increased by 21.47% in one year.
| Shares Outstanding | 18.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.99% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.57M |
| Failed to Deliver (FTD) Shares | 22.70K |
| FTD / Avg. Volume | 18.04% |
Short Selling Information
The latest short interest is 162.90K, so 0.86% of the outstanding shares have been sold short.
| Short Interest | 162.90K |
| Short % of Shares Out | 0.86% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 1.15 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -46.25.
| PE Ratio | -0.25 |
| Forward PE | -46.25 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.35 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Chemomab Therapeutics Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 0.
| Current Ratio | 4.32 |
| Quick Ratio | 4.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.43% and return on capital (ROIC) is -146.41%.
| Return on Equity (ROE) | -1.43% |
| Return on Assets (ROA) | -1.09% |
| Return on Capital (ROIC) | -146.41% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.21M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 214.85% in the last 52 weeks. The beta is 0.3, so Chemomab Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | 214.85% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 1.2 |
| Relative Strength Index (RSI) | 52.41 |
| Average Volume (20 Days) | 125.81K |
Income Statement
In the last 12 months, Chemomab Therapeutics Ltd. had revenue of $0 and earned -$24.22M in profits. Earnings per share was $-2.06.
| Revenue | 0 |
| Gross Profit | -66.83K |
| Operating Income | -25.46M |
| Net Income | -24.22M |
| EBITDA | -25.39M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.06 |
Balance Sheet
The company has $9.29M in cash and $392.00K in debt, giving a net cash position of $8.90M.
| Cash & Cash Equivalents | 9.29M |
| Total Debt | 392.00K |
| Net Cash | 8.90M |
| Retained Earnings | -88.68M |
| Total Assets | 20.90M |
| Working Capital | 15.54M |
Cash Flow
In the last 12 months, operating cash flow was -$23.61M and capital expenditures -$3.00K, giving a free cash flow of -$23.61M.
| Operating Cash Flow | -23.61M |
| Capital Expenditures | -3.00K |
| Free Cash Flow | -23.61M |
| FCF Per Share | -2.01 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -129.56% |
| FCF Yield | -78.76% |
Analyst Forecast
The average price target for CMMB is $7, which is 340.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 340.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 17, 2021. It was a backward split with a ratio of 1:16.
| Last Split Date | Mar 17, 2021 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | -4.04 |
| Piotroski F-Score | 2 |